(IFF) International Flavors - Overview
Stock: Flavors, Fragrances, Ingredients, Enzymes, Excipients
| Risk 5d forecast | |
|---|---|
| Volatility | 44.4% |
| Relative Tail Risk | -7.44% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.41 |
| Alpha | -28.19 |
| Character TTM | |
|---|---|
| Beta | 0.648 |
| Beta Downside | 0.639 |
| Drawdowns 3y | |
|---|---|
| Max DD | 42.62% |
| CAGR/Max DD | -0.08 |
EPS (Earnings per Share)
Revenue
Description: IFF International Flavors March 01, 2026
International Flavors & Fragrances Inc. (NYSE: IFF) is a global specialty-chemicals company that develops and sells ingredients across four segments: Nourish (natural-based food ingredients and flavorings), Health & Biosciences (enzymes, cultures, and animal-nutrition solutions), Scent (fragrance compounds), and Pharma Solutions (cellulosic and seaweed-derived excipients). Headquartered in New York and operating in the U.S., Europe, and beyond, IFF leverages its extensive R&D platform to serve food-and-beverage, personal-care, and pharmaceutical markets.
In its most recent fiscal year (FY 2025), IFF reported net sales of $10.9 billion, up 7% year-over-year, with an adjusted earnings-per-share of $6.68 and an operating margin of 15.2%. The Nourish segment drove the bulk of growth, posting a 9% sales increase, largely on plant-based protein and clean-label flavor solutions. Free cash flow reached $1.2 billion, supporting a 4% dividend yield and a $3 billion share-repurchase program.
Key sector drivers include the accelerating consumer shift toward natural and sustainable ingredients-global plant-based protein demand is projected to grow at a 12% CAGR through 2030-and the expanding fragrance market, which is expected to reach $55 billion by 2027, fueled by premium personal-care and home-fragrance trends. IFF’s focus on bio-based technologies and strategic acquisitions positions it to capture a larger share of these growth tails.
For a deeper dive, you might explore ValueRay’s analyst notes on IFF.
Headlines to watch out for
- Global consumer demand for packaged food and beverages impacts revenue
- Commodity price fluctuations affect input costs for ingredients
- Regulatory changes in food and fragrance industries pose compliance risks
- Innovation in natural and sustainable ingredients drives market share
- Currency exchange rate volatility impacts international sales and profits
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income: -348.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA -1.10 > 1.0 |
| NWC/Revenue: 15.25% < 20% (prev 31.87%; Δ -16.62% < -1%) |
| CFO/TA 0.03 > 3% & CFO 850.0m > Net Income -348.0m |
| Net Debt (6.06b) to EBITDA (809.0m): 7.49 < 3 |
| Current Ratio: 1.42 > 1.5 & < 3 |
| Outstanding Shares: last quarter (257.0m) vs 12m ago 0.39% < -2% |
| Gross Margin: 34.93% > 18% (prev 0.36%; Δ 3.46k% > 0.5%) |
| Asset Turnover: 40.18% > 50% (prev 40.06%; Δ 0.12% > 0%) |
| Interest Coverage Ratio: -0.67 > 6 (EBITDA TTM 809.0m / Interest Expense TTM 229.0m) |
Altman Z'' -0.49
| A: 0.07 (Total Current Assets 5.59b - Total Current Liabilities 3.93b) / Total Assets 25.54b |
| B: -0.13 (Retained Earnings -3.42b / Total Assets 25.54b) |
| C: -0.01 (EBIT TTM -153.0m / Avg Total Assets 27.10b) |
| D: -0.42 (Book Value of Equity -4.81b / Total Liabilities 11.35b) |
| Altman-Z'' Score: -0.49 = B |
Beneish M -3.00
| DSRI: 1.07 (Receivables 2.00b/1.97b, Revenue 10.89b/11.48b) |
| GMI: 1.03 (GM 34.93% / 35.91%) |
| AQI: 1.05 (AQ_t 0.60 / AQ_t-1 0.57) |
| SGI: 0.95 (Revenue 10.89b / 11.48b) |
| TATA: -0.05 (NI -348.0m - CFO 850.0m) / TA 25.54b) |
| Beneish M-Score: -3.00 (Cap -4..+1) = A |
What is the price of IFF shares?
Over the past week, the price has changed by -5.64%, over one month by -16.13%, over three months by +9.14% and over the past year by -10.01%.
Is IFF a buy, sell or hold?
- StrongBuy: 10
- Buy: 7
- Hold: 4
- Sell: 0
- StrongSell: 1
What are the forecasts/targets for the IFF price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 90.7 | 32% |
| Analysts Target Price | 90.7 | 32% |
IFF Fundamental Data Overview March 14, 2026
P/S = 1.7361
P/B = 1.4121
P/EG = 0.8993
Revenue TTM = 10.89b USD
EBIT TTM = -153.0m USD
EBITDA TTM = 809.0m USD
Long Term Debt = 4.74b USD (from longTermDebt, last quarter)
Short Term Debt = 1.36b USD (from shortTermDebt, last quarter)
Debt = 6.65b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 6.06b USD (from netDebt column, last quarter)
Enterprise Value = 24.97b USD (18.91b + Debt 6.65b - CCE 590.0m)
Interest Coverage Ratio = -0.67 (Ebit TTM -153.0m / Interest Expense TTM 229.0m)
EV/FCF = 97.53x (Enterprise Value 24.97b / FCF TTM 256.0m)
FCF Yield = 1.03% (FCF TTM 256.0m / Enterprise Value 24.97b)
FCF Margin = 2.35% (FCF TTM 256.0m / Revenue TTM 10.89b)
Net Margin = -3.20% (Net Income TTM -348.0m / Revenue TTM 10.89b)
Gross Margin = 34.93% ((Revenue TTM 10.89b - Cost of Revenue TTM 7.09b) / Revenue TTM)
Gross Margin QoQ = 29.20% (prev 36.49%)
Tobins Q-Ratio = 0.98 (Enterprise Value 24.97b / Total Assets 25.54b)
Interest Expense / Debt = 0.74% (Interest Expense 49.0m / Debt 6.65b)
Taxrate = 18.18% (4.00m / 22.0m)
NOPAT = -125.2m (EBIT -153.0m * (1 - 18.18%)) [loss with tax shield]
Current Ratio = 1.42 (Total Current Assets 5.59b / Total Current Liabilities 3.93b)
Debt / Equity = 0.47 (Debt 6.65b / totalStockholderEquity, last quarter 14.15b)
Debt / EBITDA = 7.49 (Net Debt 6.06b / EBITDA 809.0m)
Debt / FCF = 23.68 (Net Debt 6.06b / FCF TTM 256.0m)
Total Stockholder Equity = 13.99b (last 4 quarters mean from totalStockholderEquity)
RoA = -1.28% (Net Income -348.0m / Total Assets 25.54b)
RoE = -2.49% (Net Income TTM -348.0m / Total Stockholder Equity 13.99b)
RoCE = -0.82% (EBIT -153.0m / Capital Employed (Equity 13.99b + L.T.Debt 4.74b))
RoIC = -0.59% (negative operating profit) (NOPAT -125.2m / Invested Capital 21.11b)
WACC = 6.30% (E(18.91b)/V(25.56b) * Re(8.30%) + D(6.65b)/V(25.56b) * Rd(0.74%) * (1-Tc(0.18)))
Discount Rate = 8.30% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.39%
[DCF] Terminal Value 78.66% ; FCFF base≈394.4m ; Y1≈258.9m ; Y5≈118.1m
[DCF] Fair Price = N/A (negative equity: EV 3.35b - Net Debt 6.06b = -2.71b; debt exceeds intrinsic value)
EPS Correlation: -41.08 | EPS CAGR: -18.08% | SUE: -0.21 | # QB: 0
Revenue Correlation: -82.25 | Revenue CAGR: -5.70% | SUE: 1.88 | # QB: 3
EPS next Quarter (2026-06-30): EPS=1.17 | Chg7d=-0.009 | Chg30d=-0.017 | Revisions Net=+0 | Analysts=12
EPS current Year (2026-12-31): EPS=4.45 | Chg7d=-0.005 | Chg30d=-0.026 | Revisions Net=-2 | Growth EPS=+5.9% | Growth Revenue=-1.7%
EPS next Year (2027-12-31): EPS=4.80 | Chg7d=+0.002 | Chg30d=-0.019 | Revisions Net=-2 | Growth EPS=+8.0% | Growth Revenue=+3.0%
[Analyst] Revisions Ratio: +0.00 (3 Up / 3 Down within 30d for Next Quarter)